Hybridoma cell lines producing antibodies to RSV NS1

This technology provides a new set of hybridoma cell lines each expressing a single monoclonal antibody against human respiratory syncytial virus (RSV) nonstructural protein 1 (NS1). These antibodies have variously been shown to detect NS1 protein in an enzyme-linked immunosorbent assay (ELISA), Western blot assay, immunofluorescence microscopy of paraformaldehyde-fixed cells, and flow cytometry. The various antibodies can vary in their efficiency in each of these assays. This technology provides a unique set of qualified monoclonal antibodies against RSV NS1 protein which currently do not exist. These antibodies and cell lines may be of interest to any persons investigating RSV infection processes, particularly as it relates to the activity of NS1 in such an infection process.This technology is available for licensing for commercial development in accordance with 35 U.S.C. § 209 and 37 CFR Part 404, as well as for further development and evaluation under a research collaboration.IC: NIAIDNIH Ref. No.: E-167-2018-0Advantages: Ease of manufactureUnique research toolApplications: Viral diagnosticsVaccine researchProvider Technology ID: 3339Updated On: Oct 18, 2018Date Published: Thursday, October 18, 2018Provider Classifications: Publications: Licensing Contacts: Lead Inventor: Inventor IC: NIAIDNIAIDNIAIDInventor Lab URL: http://irp.nih.gov/pi/peter-collinsLPM FIrst Name: PeterLPM Last Name: SoukasLPM ...

Source: NIH OTT Licensing Opportunities - October 18, 2018 Category: Research Authors: ajoyprabhu3 Source Type: research